Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26462599 | 0.91 | RAB9A (0.51) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL2852071 | 0.86 | MAOB (0.58) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL214564 | 0.86 | RAB9A (0.46) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL15173730 | 0.85 | MAOB (0.56) | MAOBRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL30040891 | 0.84 | MAOB (0.63) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL4473165 | 0.84 | MAOB (0.63) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL8335885 | 0.84 | ALOX5 (0.61) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL4324579 | 0.83 | MAOB (0.60) | MAOBRAB9AMAOASMN1; SMN2NPC1 | |
| SCHEMBL23273767 | 0.83 | MAOB (0.49) | MAOBRAB9AL3MBTL1MAPTMAOA | |
| SCHEMBL749857 | 0.83 | MEN1 (0.59) | MAOBRAB9AL3MBTL1MAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| CN-116669725-A | Novel aminopyridine and use thereof in the treatment of cancer | 奥克兰联合服务有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4217357-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Auckland Uniservices Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-4048659-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| EP-1009748-A1 | 3-ALKYLPYRROLO 3,2-$i(c)]QUINOLINE DERIVATIVES | Korea Research Institute of Chemical Technology (KR) | 2000-06-21 | — | — | EP | disclosed |
| WO-2000001696-A1 | 3-ALKYLPYRROLO[3,2-c]QUINOLINE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2000-01-13 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| US-5622967-A | NERVOUS SYSTEM DISORDERS | STERLING WINTHROP, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0094052-A2 | 1-(1,3-Dioxolan-2-yl-methyl)-1H-imidazoles and -1H-1,2,4-triazoles and their salts, process for their preparation, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-16 | — | — | EP | disclosed |
| US-3995041-A | CORONARY VASODILATORS | MILES LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | MAOB 4550/4885RAB9A 1814/4885L3MBTL1 867/4885 |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | STUB1, MDM2, UBE3A | MAOB 3544/4885RAB9A 2413/4885L3MBTL1 854/4885 |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | MAOB 2336/4885RAB9A 1307/4885L3MBTL1 2910/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | MAOB 3544/4885RAB9A 2413/4885L3MBTL1 854/4885 |
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | MAOB 2029/4885RAB9A 1305/4885L3MBTL1 3010/4885 |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | MAOB 2423/4885RAB9A 3496/4885L3MBTL1 4260/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MAOB 1738/4885RAB9A 1897/4885L3MBTL1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.